Synthesis and pharmacological characterization of potent, selective, and orally bioavailable isoindoline class dipeptidyl peptidase IV inhibitors
Open Access
- 1 January 2011
- journal article
- Published by Springer Science and Business Media LLC in BMC Chemistry
- Vol. 1 (1), 7
- https://doi.org/10.1186/2191-2858-1-7
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetesBioorganic & Medicinal Chemistry, 2009
- Dipeptidyl Peptidase-4 InhibitorsDiabetes Care, 2007
- Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With MetforminDiabetes Care, 2007
- Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 DiabetesDiabetes Care, 2007
- Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 DiabetesDiabetes Care, 2006
- Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 DiabetesDiabetes, 2005
- Dipeptidyl Peptidase IV Inhibitors for the Treatment of DiabetesJournal of Medicinal Chemistry, 2004
- Enhancing Incretin Action for the Treatment of Type 2 DiabetesDiabetes Care, 2003
- Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 DiabetesDiabetes Care, 2002
- Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2001